StockNews.com Initiates Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

Research analysts at StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report issued to clients and investors on Saturday. The brokerage set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets dropped their target price on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a research report on Monday, November 11th.

NovaBay Pharmaceuticals Trading Down 0.8 %

Shares of NBY opened at $0.61 on Friday. The business’s 50-day moving average price is $0.65 and its 200 day moving average price is $0.62. The stock has a market capitalization of $2.96 million, a P/E ratio of -0.01 and a beta of 0.67. NovaBay Pharmaceuticals has a 1-year low of $0.36 and a 1-year high of $9.08.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.